Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 9,511 | 9,771 | 10,929 | 13,363 | 11,390 |
| Cost of Goods | 8,221 | 8,441 | 9,670 | 11,096 | 9,671 |
| Gross Profit | 1,290 | 1,330 | 1,259 | 2,267 | 1,720 |
| Operating Expenses | 3,084 | 4,364 | 2,220 | 1,307 | 1,117 |
| Operating Income | -1,574 | -2,594 | -291 | 1,056 | 1,274 |
| Interest Expense | 148 | 69 | 0 | 0 | 0 |
| Other Income | 127 | 55 | -13 | -13 | -11 |
| Pre-tax Income | -1,595 | -2,608 | -304 | 1,043 | 1,263 |
| Income Tax | 4 | 22 | 52 | 291 | 168 |
| Net Income Continuous | -1,598 | -2,629 | -356 | 752 | 1,094 |
| Net Income | $-1,598 | $-2,629 | $-356 | $752 | $1,094 |
| EPS Basic Total Ops | -0.09 | -0.17 | -0.46 | 0.48 | 1.44 |
| EPS Basic Continuous Ops | -0.09 | -0.17 | -0.25 | 0.53 | 1.28 |
| EPS Diluted Total Ops | -0.09 | -0.17 | -0.46 | 0.48 | 1.44 |
| EPS Diluted Continuous Ops | -0.09 | -0.17 | -0.25 | 0.53 | 1.28 |
| EPS Diluted Before Non-Recurring Items | -0.09 | -1.80 | 0.00 | 0.00 | N/A |
| EBITDA(a) | $-1,273 | $-2,417 | $-186 | $1,164 | $1,375 |